Try these holistic remedies to get relief for irritated skin.

The US FDA has approved Nemluvio (nemolizumab) for the treatment of moderate-to-severe atopic dermatitis in patients aged 12 years and older.

The following is a summary of “Prevalence and clinical impact of topical corticosteroid phobia among patients with chronic ...

The global hand eczema treatment market is projected to experience robust growth, with a market value of USD 53 million in ...

According to Zhang Jianzhong, leading investigator of Zedman's clinical studies at Peking University People's Hospital, eczema is the number one skin disease that affects over 80 million people in ...

The FDA has approved Nemluvio for the treatment of moderate to severe atopic dermatitis in adults and pediatric patients 12 years and older.

Nonspecific anti-inflammatories like steroids might be entirely sidelined for mild-to-moderate chronic hand eczema now that three targeted topical agents are available.

Rebecca Ebbage says she feels 'like a burns victim' after her body became engulfed in itchy and weeping sores and she was ...

A monoclonal antibody that targets interleukin (IL)-31 receptor alpha, nemolizumab is specifically indicated for individuals ...

Switzerland’s Galderma has won US Food and Drug Administration (FDA) approval for the use of Nemluvio (nemolizumab) for ...

The US FDA has approved Galderma's Nemluvio (nemolizumab), for individuals aged 12 years and above with moderate-to-severe atopic dermatitis.

The FDA has blessed two previously approved medicines—one a cream and the other an injection—to treat atopic dermatitis (AD).